Key result
Perioperative dexmedetomidine did not decrease the number of analgesic requirements in the first 72 hours compared to saline in patients undergoing lateral thoracotomy.
Why the study?
Dexmedetomidine is widely used as an adjunct to general anesthesia, but its effects on postoperative analgesia in patients undergoing lateral thoracotomy for thoracic esophageal cancer required evaluation.
Does perioperative dexmedetomidine reduce analgesic requirements in patients undergoing lateral thoracotomy for thoracic esophageal cancer?
RCT (n=62)
Double-Blind
randomized
Does perioperative dexmedetomidine reduce analgesic requirements in patients undergoing lateral thoracotomy for thoracic esophageal cancer?
Answers are grounded in this paper and cite their sources.
Perioperative dexmedetomidine does not reduce postoperative analgesic requirements in patients undergoing lateral thoracotomy for esophageal cancer, though it may decrease intraoperative opioid use and improve sleep quality.
Objectives . Dexmedetomidine is widely used as an adjunct to general anesthesia. In this study, we evaluated the effects of perioperative dexmedetomidine infusion on postoperative analgesia in patients undergoing lateral thoracotomy for thoracic esophageal cancer. Methods . A total of 62 patients undergoing lateral thoracotomy for thoracic esophageal cancer were randomized to receive adjuvant therapy with either dexmedetomidine (0.5 μ g/kg intravenous bolus injection for 10 min before induction of anesthesia, followed by continuous infusion of 0.2–0.4 μ g/kg/h until the end of surgery, and 0.06 μ g/kg/h for 5 days after surgery) or equal volumes of saline. Acute postoperative pain was treated with patient-controlled intravenous sufentanil and flurbiprofen axetil. The primary outcomes of this study were the numbers of analgesic requirements in the first postoperative 72 h. Results . Perioperative dexmedetomidine did not decrease the numbers of analgesic requirements in the first postoperative 72 h (dexmedetomidine group: 12.14 ± 4.76, saline group: 10.89 ± 5.66; p=0.367). Likewise, the groups did not differ with respect to total postoperative analgesic requirements, postoperative pain, perioperative inflammation, blood cell count, incidence of adverse events, surgical recovery (assessed at postoperative days 2 and 5 using the surgical recovery scale), length of hospital stay, hospital cost, incidence of chronic pain, or quality of life. Notably, dexmedetomidine had beneficial effects on decreasing intraoperative opioid consumption and improving postoperative sleep quality. Discussion . Perioperative dexmedetomidine has limited analgesic benefits in lateral thoracotomy for esophageal cancer when added to an opioid-based multimodal anesthetic regimen but can reduce opioid consumption.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2020) conducted an RCT in Thoracic esophageal cancer (n=62). Dexmedetomidine vs. Saline was evaluated on Numbers of analgesic requirements in the first postoperative 72 h (p=0.367). Perioperative dexmedetomidine did not decrease the number of analgesic requirements in the first 72 hours compared to saline in patients undergoing lateral thoracotomy.
Synapse has enriched 10 related papers. Consider them for comparative context: